Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is trading at $84.72, about ₹8,138 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, down 1.25% today. Indian residents can buy Spyre Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$83.26
Today's high
$86.51
52 week low
$15.82
52 week high
$110.18
SYRE opened at $85.78, closed previously at $85.79, and has traded between $15.82 and $110.18 over the past 52 weeks.
About
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Key statistics
Avg. volume
1.25M
Market cap
$7.36B
P/E Ratio
-43.45
Price-to-sales ratio
81.30
Enterprise value
$2.01B
Free cash flow yield
-8.07%
Debt-to-equity ratio
0.00
Return on equity
-21.70%
ROIC
-29.14%
Beta
3.00
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$0.00
Earnings per share
-$1.98
Free cash flow
-$169.25M
Net profit margin
-197.71%
Gross margin
0.00%
EBITDA
-$209.56M
Revenue growth
0.00%
Similar securities
This is not an investment recommendation
How to buy Spyre Therapeutics from India
Indian residents can buy Spyre Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Spyre Therapeutics and place an order
Find Spyre Therapeutics by name or by its ticker, SYRE, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Spyre Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Spyre Therapeutics position in USD and INR. Spyre Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Spyre Therapeutics from India
Trading and taxes when buying Spyre Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneSpyre Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Spyre Therapeutics stock?
Yes. Spyre Therapeutics (SYRE) has been listed on NASDAQ since 2016, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Spyre Therapeutics share cost in rupees?
One Spyre Therapeutics share is $84.72 — about ₹8,138 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Spyre Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Spyre Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Spyre Therapeutics?
Yes. One Spyre Therapeutics share is $84.72, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Spyre Therapeutics.
How are gains on Spyre Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Spyre Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Spyre Therapeutics pay a dividend?
No. Spyre Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Spyre Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Spyre Therapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Spyre Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Spyre Therapeutics holding, its cost and its closing value.
How do I sell Spyre Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.